๎
๎ผ
๋ก๊ทธ์ธ
๎
AbbVie Inc
ABBV207.111USD
+2.181+1.06%
์ข
๊ฐย 03/25, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
327.37B์๊ฐ์ด์ก
87.52P/E TTM
๎
์์ธํ ๋ด์ฉ์ AbbVie Inc ํ์ฌ
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
AbbVie Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ ABBV
ํ์ฌ ์ด๋ฆAbbVie Inc
์์ฅ์ผJan 02, 2013
CEOMichael (Robert A)
์ง์ ์55000
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJan 02
์ฃผ์1 N Waukegan Rd
๋์NORTH CHICAGO
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX NASDAQ Basic NYSE
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ60064
์ ํ18479327900
์น์ฌ์ดํธhttps://www.abbvie.com/
์ข
๋ชฉ ์ฝ๋ ABBV
์์ฅ์ผJan 02, 2013
CEOMichael (Robert A)
AbbVie Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.27K
+10.04%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.89%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
52.38K
+19.28%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.80%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.13%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.37%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.15%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.29%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+47.64%
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.27K
+10.04%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.89%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
52.38K
+19.28%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.80%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.13%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.37%
์์ต ๋ถ์
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Jan 6
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Immunology-SKYRIZI
4.71B
29.84%
Immunology-RINVOQ
2.18B
13.84%
Immunology-HUMIRA
993.00M
6.29%
Neuroscience-Botox Therapeutic
985.00M
6.24%
Neuroscience-Vraylar
934.00M
5.92%
๊ธฐํ
5.97B
37.85%
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
United States
11.53B
73.07%
International
3.35B
21.21%
All other countries
660.00M
4.18%
Collaboration revenue
243.00M
1.54%
์ฌ์
๋ณ
์ง์ญ๋ณ
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Immunology-SKYRIZI
4.71B
29.84%
Immunology-RINVOQ
2.18B
13.84%
Immunology-HUMIRA
993.00M
6.29%
Neuroscience-Botox Therapeutic
985.00M
6.24%
Neuroscience-Vraylar
934.00M
5.92%
๊ธฐํ
5.97B
37.85%
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Feb 12
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Feb 12
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.97%
๊ธฐํ
75.38%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.97%
๊ธฐํ
75.38%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
44.71%
Investment Advisor/Hedge Fund
21.14%
Research Firm
3.07%
Pension Fund
2.32%
Bank and Trust
2.30%
Sovereign Wealth Fund
1.54%
Insurance Company
0.67%
Hedge Fund
0.46%
Family Office
0.22%
๊ธฐํ
23.57%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
2023Q3
4666
1.27B
72.28%
+8.75M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
The Vanguard Group, Inc.
176.93M
10.01%
+427.57K
+0.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
92.78M
5.25%
+679.67K
+0.74%
Sep 30, 2025
State Street Investment Management (US)
79.82M
4.52%
-202.47K
-0.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
40.44M
2.29%
+1.26M
+3.22%
Sep 30, 2025
JP Morgan Asset Management
36.42M
2.06%
-1.05M
-2.81%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
23.10M
1.31%
-1.99M
-7.94%
Jun 30, 2025
Capital Research Global Investors
25.23M
1.43%
-34.75K
-0.14%
Sep 30, 2025
Charles Schwab Investment Management, Inc.
25.96M
1.47%
-825.22K
-3.08%
Sep 30, 2025
Fidelity Management & Research Company LLC
19.95M
1.13%
+301.27K
+1.53%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
23.97M
1.36%
+460.64K
+1.96%
Sep 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
๋ ๋ณด๊ธฐ
VanEck Pharmaceutical ETF
๋น์จ9.64%
First Trust NASDAQ Pharmaceuticals ETF
๋น์จ8.05%
Health Care Select Sector SPDR Fund
๋น์จ7.89%
Proshares Ultra Health Care
๋น์จ7.62%
iShares U.S. Healthcare ETF
๋น์จ7.57%
JPMorgan Healthcare Leaders ETF
๋น์จ6.87%
Simplify Health Care ETF
๋น์จ6.73%
Fidelity MSCI Health Care Index ETF
๋น์จ6.5%
Harbor Health Care ETF
๋น์จ6.18%
iShares Core High Dividend ETF
๋น์จ5.9%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
40.87B
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
Feb 19, 2026
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option
Apr 15, 2026
May 15, 2026
Apr 15, 2026
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
๋ ๋ณด๊ธฐ
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
